Tag Archives: biotech industry

Newron Announces Positive Results for Ralfinamide

Newron Pharmaceuticals SpA, announced positive preclinical study results showing that ralfinamide has statistically significant benefits against spontaneous chronic pain in an experimental model of central pain. Ralfinamide has shown positive results in chronic pain on CNS targets, in addition to its known peripheral mechanisms; Ralfinamide’s unique ability to affect central targets widens its broad spectrum of analgesic mechanisms, supporting its therapeutic potential for alleviating Neuropathic Low Back Pain (NLBP) in the ongoing SERENA Phase IIb/III Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Flu Study Finds Only One H1N1 Vaccine Shot Needed

Early results from clinical trials show that the majority of healthy adults may only need one vaccine shot rather than two to protect against the H1N1 virus. Results are showing that the effects of the vaccine are starting faster than expected. Those results could mean that the limited vaccine supply, with an estimated 45 million doses to be made available next month because of poorer-than-expected yields from growing the virus in chicken eggs, could be Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , ,

Team at BrainCells using brain cells

An interview with James A. Schoeneck, Chief Executive Officer, BrainCells, Inc.: Can you describe the top priorities or upcoming milestones for your company? BrainCells Inc. has two up-coming milestones in 1Q10: the advancement of BCI-632 into a Phase 1 clinical trial, and Phase 2 data for BCI-540 in patients with treatment resistant depression and anxiety. Both compounds have novel mechanisms of action.  In July, the company announced the outcome of an exploratory Phase 2 study Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Anadys Pharmaceuticals Begins Phase II Study Dosing of ANA598

Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that dosing has begun in a Phase II trial of ANA598 in patients chronically infected with hepatitis C virus (HCV). The study will evaluate ANA598 over 12 weeks, taken in combination with pegylated interferon-alpha and ribavirin, in treatment naïve HCV patients. ANA598 is an investigational, oral, nonnucleoside polymerase inhibitor. Anadys has completed three Phase I clinical studies of ANA598 that have demonstrated potent antiviral activity and good tolerability. Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

XOMA Collaboration with Arana Therapeutics

XOMA Ltd. (Nasdaq:XOMA) and Arana Therapeutics Limited, a wholly-owned subsidiary of Cephalon, Inc. (Nasdaq:CEPH) will collaborate on multiple proprietary XOMA antibody R&D technologies, including a new antibody phage display library, and a suite of integrated information and data management systems. Arana will pay XOMA a fee of $6 million and XOMA will receive milestone payments and royalties on product sales. The proprietary antibody library covered by the collaboration is one of a series of proprietary Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,